Core Viewpoint - CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing regRNA-targeting therapeutics aimed at restoring healthy protein levels in various genetic diseases [1]. Group 1: Conference Participation - CAMP4 will present and hold one-on-one meetings at the Piper Sandler 36th Annual Healthcare Conference from December 3rd to 5th, 2024 [1]. - The presentation is scheduled for December 5, 2024, from 1:00 to 1:25 PM ET, and a live webcast will be available on the company's investor relations website [2]. Group 2: Company Overview - CAMP4 is developing disease-modifying treatments for over 1,200 genetic diseases by amplifying healthy protein levels through its proprietary RAP Platform™, which targets regRNAs that regulate gene expression [4]. - The company's approach involves using ASO drug candidates to amplify mRNA, which may provide therapeutic benefits in conditions characterized by haploinsufficiency and recessive partial loss-of-function disorders [4].

Core Insights - CAMP4 Therapeutics Corporation successfully completed its Initial Public Offering (IPO), raising gross proceeds of $82.1 million, which positions the company for continued growth and development of its programs [1][3][4] - The company has made significant progress in its lead program, CMP-CPS-001, which has received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA, indicating its potential as a novel therapeutic for urea cycle disorders [2][3] - CAMP4 has entered a strategic research collaboration with BioMarin, valued at over $370 million, to leverage its RNA Actuating Platform for identifying therapeutics targeting regRNAs associated with genetic diseases [1][2][3] Financial Performance - For the third quarter of 2024, CAMP4 reported a net loss of $13.5 million, compared to a net loss of $11.7 million for the same period in 2023 [7][12] - Research and Development (R&D) expenses were $9.7 million for Q3 2024, slightly down from $9.8 million in Q3 2023, primarily due to a reduction in workforce-related expenses [5] - General and Administrative (G&A) expenses increased to $3.8 million in Q3 2024 from $2.9 million in Q3 2023, mainly due to higher stock-based compensation and patent-related expenses [6] Clinical Development - The Phase 1 clinical trial of CMP-CPS-001 has completed dosing for all Single Ascending Dose (SAD) cohorts, with safety data expected to be reported in Q1 2025 [1][3] - Following the SAD data, the company anticipates reporting Multiple Ascending Dose (MAD) biomarker efficacy data in the second half of 2025, which may enable a registrational Phase 2/3 study [2][3] Cash Position - As of September 30, 2024, CAMP4 had $2.5 million in cash and cash equivalents, but on a pro forma basis, considering the IPO proceeds, the company is well-positioned for future growth [4][12]

Group 1 - CAMP4 Therapeutics Corporation priced its initial public offering of 6.82 million shares at $11.00 per share, raising approximately $75 million in gross proceeds [1] - The company is focused on RNA therapeutics for rare diseases and has initiated a Phase 1 study for CMP-CPS-001 targeting urea cycle disorders [1] - CMP-CPS-001 has received FDA Orphan Drug and Rare Pediatric Disease Designations [1] Group 2 - CAMP4 announced a research collaboration with BioMarin Pharmaceutical Inc to develop therapeutics that target regulatory RNA sequences [2] - BioMarin has the right to select two targets from CAMP4's RAP Platform for clinical development [2] Group 3 - William Blair initiated coverage on CAMP4, highlighting its lower market cap compared to other early-stage genetic medicine companies despite its innovative RAP platform [3] - Piper Sandler also initiated coverage, suggesting that regulatory RNAs could represent a significant advancement over traditional therapies [3] Group 4 - Piper's analysis indicates that an increase in ureagenesis rate test (URT) would signal the effectiveness of CMP-CPS-001 in lowering ammonia levels [4] - The analyst anticipates registrational Phase 2 studies for urea cycle disorders and potential FDA approval by 2029, with projected peak revenues of $1.0 billion by 2036 [4] - Piper has set an Overweight rating for CAMP4 with a price target of $18 [4] Group 5 - CAMP stock has increased by 13.5%, trading at $9.33 [5]

Company Overview - CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing regulatory RNA-targeting therapeutics aimed at restoring healthy protein levels for various genetic diseases [5] - The company utilizes its proprietary RAP Platform™ to map regulatory RNAs and create therapeutic candidates targeting genes associated with over 1,200 disorders [5] Initial Public Offering (IPO) Details - CAMP4 announced the pricing of its IPO, offering 6,820,000 shares at $11.00 per share, with expected gross proceeds of approximately $75.0 million before expenses [1] - The common stock is set to begin trading on the Nasdaq Global Market under the ticker symbol "CAMP" on October 11, 2024, with the offering expected to close on October 15, 2024, subject to customary conditions [1] - Underwriters have a 30-day option to purchase an additional 1,023,000 shares at the IPO price [1] Underwriters - J.P. Morgan, Leerink Partners, Piper Sandler, and William Blair are acting as joint book-running managers for the offering [2]

Group 1 - The article discusses the services provided by IPO Edge, which includes actionable information on growth stocks through first-look S-1 filings, previews on upcoming IPOs, an IPO calendar, a database of U.S. IPOs, and a comprehensive guide to IPO investing [1]

CARLSBAD, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- OEM Off-Highway, the nationally recognized magazine serving product development teams for mobile OEMs globally, has selected the HMU-3640LB Industrial IoT Gateway as one of the favored new mobile on- and off-road equipment products of 2024. The 2024 Top New Products represent the top new product introductions that exhibit innovation, quality, efficiency, and productivity in the mobile on- and off-road equipment manufacturing space. The awarded products ar ...

CARLSBAD, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- CalAmp Corp. ("CalAmp"), a telematics company that provides products and solutions that help organizations monitor, track and protect vital assets, is pleased to announce the appointment of Thomas Ayers as General Manager of its Edge Device business. In this role, Ayers will spearhead the growth and innovation of CalAmp's edge device portfolio, leveraging his extensive expertise in hardware development and leading-edge technology. Ayers brings to CalAmp de ...

CARLSBAD, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- CalAmp, a global leader in telematics solutions, is excited to announce the launch of the new Inventory Manager feature. This feature is designed to reduce operational friction and streamline the device onboarding process by providing enhanced visibility and oversight of shipped products. The Inventory Manager offers comprehensive oversight of all ordered products, simplifying the provisioning process before devices are even turned on. This enhancement ens ...

CalAmp successfully completed restructuring in less than 60 days Emerges as private company with enhanced liquidity to invest in innovation to support customers' evolving needs CARLSBAD, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- CalAmp, Inc. ("CalAmp"), a telematics company that provides products and solutions that help organizations monitor, track and protect vital assets, is pleased to announce that it is now a private company owned by Lynrock Lake Master Fund LP ("Lynrock Lake" or "Lynrock"), a fund mana ...

IRVINE, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- CalAmp, a telematics company that provides products and solutions that help organizations monitor, track and protect vital assets, today announced the appointment of Paul Washicko as the new Senior Vice President of Product Management. In his role, Washicko will lead an accomplished team across the company's telematics portfolio of hardware and software solutions, driving innovation and growth. Washicko is no stranger to CalAmp, having previously led the com ...